"Fas Ligand Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.
| Descriptor ID |
D053222
|
| MeSH Number(s) |
D12.644.276.374.750.249 D12.776.395.550.312 D12.776.467.374.750.249 D12.776.543.550.312 D23.529.374.750.249
|
| Concept/Terms |
Fas Ligand Protein- Fas Ligand Protein
- CD95L
- Fas Ligand (FasL)
- FasL Protein
- TNF Superfamily, Member 6
- CD178 Antigen
- Antigen, CD178
- Antigens, CD178
- Fas Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 6
- CD178 Antigens
- CD95 Antigen Ligand
- CD95 Ligand
|
Below are MeSH descriptors whose meaning is more general than "Fas Ligand Protein".
Below are MeSH descriptors whose meaning is more specific than "Fas Ligand Protein".
This graph shows the total number of publications written about "Fas Ligand Protein" by people in this website by year, and whether "Fas Ligand Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 4 | 5 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fas Ligand Protein" by people in Profiles.
-
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
-
Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J. 2021 01; 288(1):10-35.
-
The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma. Adv Exp Med Biol. 2020; 1257:75-83.
-
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Adv Exp Med Biol. 2020; 1258:177-187.
-
The role of FAS, FAS-L, BAX, and BCL-2 gene polymorphisms in determining susceptibility to unexplained recurrent pregnancy loss. J Assist Reprod Genet. 2019 May; 36(5):995-1002.
-
A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia. CNS Neurol Disord Drug Targets. 2018; 17(5):383-388.
-
Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. BMC Cancer. 2016 Feb 08; 16:70.
-
Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. Int J Cancer. 2015 Nov 15; 137(10):2454-61.
-
The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 2015 May 20; 6:7151.
-
HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res. 2015 May; 13(5):809-18.